KalVista Pharmaceuticals
KALV
KALV
101 hedge funds and large institutions have $349M invested in KalVista Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
7% more funds holding
Funds holding: 94 → 101 (+7)
4.59% more ownership
Funds ownership: 100.82% → 105.42% (+4.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
101
Holding in Top 10
3
Calls
$10.8M
Puts
$4.06M
Top Buyers
| 1 | +$8.67M | |
| 2 | +$7.6M | |
| 3 | +$3.83M | |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$3.72M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.56M |
Top Sellers
| 1 | -$4.73M | |
| 2 | -$2.81M | |
| 3 | -$2.12M | |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.77M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$975K |